

Advanced Prostate DOG Meeting

Draft Agenda

May 1, 2010

1300-1430h

Location: TBD

1. Review of minutes from Advanced Prostate DOG Teleconference 27 January 2010 (5 Minutes)
2. Current planned/upcoming studies (20 minutes)
 - a. Pre-Chemo: OGX-427 in chemo-naïve metastatic CRPC (TFRI funded, CUOG?) (Chi)
 - b. First line: Docetaxel +/- OGX-011 (CUOG?) (Chi)
 - c. Second line: Docetaxel +/- OGX-011 (CUOG?) (Hotte)
 - d. IND.195: Phase II SB939 HDAC inhibitor single agent in metastatic CRPC (NCIC CTG) (Eigl)
 - e. IND.XXX: Phase II PX-866 PI3K inhibitor single agent in metastatic CRPC (NCIC CTG) (TBD)
 - f. Status of other agents (Discussion - Everyone)
 - i. MDV3100
 - ii. ZD4054
 - iii. Dasatinib
 - iv. Ipilumimab
 - v. Sunitinib
 - vi. VEGF-Trap
 - vii. Denosumab
 - viii. Alpharadin
3. Trial Proposals (50 Minutes)
 - a. Randomized phase II of abiraterone + dutasteride vs. abiraterone (Emmenegger) (10 min)
 - b. Randomized phase III of abiraterone + prednisone vs. placebo + prednisone in M0 CRPC (Chi) (10 min)
 - c. Randomized phase III of continued vs. discontinued abiraterone after progression (Joshua) (10 min)
 - d. Phase II of Degarelix for M0 CRPC (Malone) (10 min)
 - e. MRC STAMPEDE Trial (Chi) (10 minutes)
4. Opportunities? (15 minutes) (Discussion – Everyone)
 - a. Abiraterone and MDV3100 combinations
 - b. Novel targeted agent combinations
 - c. Biomarker driven (eligibility criteria or primary endpoint) protocols